skip to main content

CORRELATION BETWEEN LIVER TRANSAMINASE ENZYME AND LEUKOCYTE COUNT IN TUBERCULOSIS PATIENTS WHO RECEIVED ANTI-TUBERCULOSIS DRUG THERAPY

Kayla Navazia Marlie  -  Medical Study Program, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia, Indonesia
Edward Kurnia Setiawan Limijadi orcid  -  Department of Clinical Pathology, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia
Meita Hendrianingtyas orcid  -  Department of Clinical Pathology, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia
*Dwi Retnoningrum orcid scopus  -  Department of Clinical Pathology, Faculty of Medicine, Universitas Diponegoro, Semarang, Indonesia

Citation Format:
Abstract

Background: While effective in treating the disease, anti-tuberculosis drugs can also potentially harm the liver. Monitoring liver health using the transaminase enzyme and leukocyte counts can help in the early detection and prevention of such damage in tuberculosis patients. Objectives: The aim of the study was to determine the correlation between transaminase enzyme levels and the leukocyte count in patients with tuberculosis who took anti-tuberculosis drugs. Methods: This research was an observational analytical study with a cross-sectional approach. It used medical record data from TB patients who met the inclusion and exclusion criteria for anti-tuberculosis drug therapy at the medical records installation. Results: Forty-four samples were included in the research. The levels of aspartate transaminase (AST), alanine transaminase (ALT), and leukocyte count were 30 IU/L, 19.5 IU/L, and 9.35x103/µL. The Spearman correlation test showed no correlation between AST and ALT levels and leukocyte counts, with p-values of 0.585 and 0.337. Conclusion: There was no correlation between AST and ALT levels and leukocyte counts in tuberculosis patients undergoing anti-tuberculosis drug therapy.

Fulltext View|Download
Keywords: Tuberculosis, AST, ALT, Leukocyte

Article Metrics:

  1. Centers for Disease Control and Prevention. Fact Sheets | General | Tuberculosis: General Information | TB [Internet]. 2011 [cited 2023 Feb 26]. Available from: https://www.cdc.gov/tb/publications/factsheets/general/tb.htm
  2. World Health Organization. Global Tuberculosis Report 2022 [Internet]. 2022. Available from: http://apps.who.int/bookorders
  3. Chai Q, Zhang Y, Liu CH. Mycobacterium tuberculosis: An adaptable pathogen associated with multiple human diseases. Front Cell Infect Microbiol. 2018 May 15;8(158)
  4. El Bouazzi O, Hammi S, Bourkadi JE, Tebaa A, Tanani DS, Soulaymani-Bencheikh R, et al. First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors. Pan Afr Med J [Internet]. 2016 Nov 16 [cited 2023 Mar 2];25:1937–8688. Available from: /pmc/articles/PMC5326068/
  5. Sun Q, Zhang Q, Gu J, Sun WW, Wang P, Bai C, et al. Prevalence, risk factors, management, and treatment outcomes of first-line antituberculous drug-induced liver injury: a prospective cohort study. Pharmacoepidemiol Drug Saf [Internet]. 2016 Aug 1 [cited 2023 Mar 5];25(8):908–17. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/pds.3988
  6. Mirlohi MS, Ekrami A, Shirali S, Ghobeishavi M, Pourmotahari F. Hematological and liver toxicity of anti-tuberculosis drugs. Electron Physician [Internet]. 2016;8(9):3005–10. Available from: http://www.ephysician.irhttp://dx.doi.org/10.19082/3010
  7. Jiang F, Yan H, Liang L, Du J, Jin S, Yang S, et al. Incidence and risk factors of anti-tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients. Liver Int. 2021 Jul 1;41(7):1565–75
  8. Zhao H, Wang Y, Zhang T, Wang Q, Xie W. Drug-Induced Liver Injury from Anti-Tuberculosis Treatment: A Retrospective Cohort Study. Med Sci Monit [Internet]. 2020 Mar 7 [cited 2023 Feb 26];26:e920350-1. Available from: /pmc/articles/PMC7077058/
  9. Mayo Clinic. Liver function tests [Internet]. 2021 [cited 2023 Feb 26]. Available from: https://www.mayoclinic.org/tests-procedures/liver-function-tests/about/pac-20394595
  10. Oh RC, Hustead TR, Ali SM, Pantsari MW. Mildly Elevated Liver Transaminase Levels: Causes and Evaluation. Am Fam Physician [Internet]. 2017 Dec 1 [cited 2023 Mar 2];96(11):709–15. Available from: https://www.aafp.org/pubs/afp/issues/2017/1201/p709.html
  11. Sabiti FB, Sa’dyah NAC. The Relationship Between Side Effects of Tuberculosis Drug Use and SGOT/SGPT Value of Intensive Phase Patients. JFSP. 2022 Dec 1;281–5
  12. Ahmed A, Kalhoro MA, Poorani K, Khokar NA, Bano S, Nazir S ur R. To Observe the Hepatotoxicity with Anti-Tuberculosis Drugs and Its Frequency and Severity. Journal of Peoples University of Medical & Health Sciences Nawabshah (JPUMHS) [Internet]. 2021 Jun 30 [cited 2023 Apr 12];11(2):57–60. Available from: http://publication.pumhs.edu.pk/index.php/ojs/article/view/23
  13. Soedarsono S, Riadi ARW. Tuberculosis Drug-Induced Liver Injury. JR. 2020 May 30;6(2):49
  14. Woolbright BL, Jaeschke H. Mechanisms of Inflammatory Liver Injury and Drug-Induced Hepatotoxicity. Curr Pharmacol Rep [Internet]. 2018 Oct 1 [cited 2023 Mar 7];4(5):346. Available from: /pmc/articles/PMC6294466/
  15. Mitroulis I, Alexaki VI, Kourtzelis I, Ziogas A, Hajishengallis G, Chavakis T. Leukocyte integrins: Role in leukocyte recruitment and as therapeutic targets in inflammatory disease. Pharmacol Ther. 2015 Mar 1;147:123–35
  16. Chedid C, Kokhreidze E, Tukvadze N, Banu S, Uddin MKM, Biswas S, et al. Association of baseline white blood cell counts with tuberculosis treatment outcome: a prospective multicentered cohort study. IJID. 2020 Nov 1;100:199–206
  17. Rohini K, Surekha Bhat M, Srikumar PS, Mahesh Kumar A. Assessment of Hematological Parameters in Pulmonary Tuberculosis Patients. Indian J Clin Biochem. 2016 Jul 1;31(3):332–5
  18. Pramono JS. Tinjauan Literatur: Faktor Risiko Peningkatan Angka Insidensi Tuberkulosis. Jurnal Ilmiah Pannmed (Pharmacyst, Analyst, Nurse, Nutrition, Midwivery, Environment, Dental Hygiene). 2021;16(1):106–13
  19. Soedarsono, Mandayani S, Prayuni K, Yuliwulandari R. The Risk Factors for Drug Induced Hepatitis in Pulmonary Tuberculosis Patients in Dr. Soetomo Hospital. IJTID [Internet]. 2018 [cited 2023 Mar 10];7(3):73–9. Available from: https://e-journal.unair.ac.id/IJTID/article/view/8689/5677
  20. Mirlohi MS, Ekrami A, Shirali S, Ghobeishavi M, Pourmotahari F. Hematological and liver toxicity of anti-tuberculosis drugs. Electron Physician [Internet]. 2016 Sep 20 [cited 2023 Apr 12];8(9):3005. Available from: /pmc/articles/PMC5074763/
  21. Giustina AD, Danielski LG, Novochadlo MM, Goldim MPS, Joaquim L, Metzker KLL, et al. Vitamin B6 reduces oxidative stress in lungs and liver in experimental sepsis. An Acad Bras Cienc [Internet]. 2019 Dec 2 [cited 2023 Sep 20];91(4):e20190434. Available from: https://www.scielo.br/j/aabc/a/DYfxS4593bPWprBFDm3cGhh/?lang=en
  22. Patti G, Pellegrino C, Ricciardi A, Novara R, Cotugno S, Papagni R, et al. Potential Role of Vitamins A, B, C, D and E in TB Treatment and Prevention: A Narrative Review. Antibiotics 2021, Vol 10, Page 1354 [Internet]. 2021 Nov 5 [cited 2023 Sep 19];10(11):1354. Available from: https://www.mdpi.com/2079-6382/10/11/1354/htm
  23. Amagon KI, Awodele O, Akindele AJ. Methionine and vitamin B‐complex ameliorate antitubercular drugs‐induced toxicity in exposed patients. Pharmacol Res Perspect [Internet]. 2017 Oct 1 [cited 2023 Sep 18];5(5):360. Available from: /pmc/articles/PMC5625164/
  24. Arfian F, Suryono S, Riyanti R. Hubungan Kadar SGOT dengan Kadar Leukosit pada Pasien NSTEMI di ICCU RSD dr. Soebandi Jember. Pustaka Kesehatan [Internet]. 2018 Jan 17 [cited 2023 Oct 5];6(1):113–7. Available from: https://jurnal.unej.ac.id/index.php/JPK/article/view/6797

Last update:

No citation recorded.

Last update:

No citation recorded.